INTEGRATED BIOPHARMA, INC. (INBP) Net margin 2018–2026
INTEGRATED BIOPHARMA, INC. (INBP) net profit margin by fiscal year — reported net income divided by reported revenue.
-6.5%FY2026 · since FY2018: 1.6% → -6.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -6.5% | -8.0 pp |
| FY2025 | 1.5% | +1.3 pp |
| FY2024 | 0.2% | +0.3 pp |
| FY2023 | -0.1% | -6.9 pp |
| FY2022 | 6.8% | -5.8 pp |
| FY2021 | 12.6% | +4.8 pp |
| FY2020 | 7.8% | +4.4 pp |
| FY2019 | 3.4% | +1.8 pp |
| FY2018 | 1.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More INBP financial trends
INBP RevenueINBP Net incomeINBP Gross profitINBP Gross marginINBP Operating incomeINBP Operating marginINBP Operating cash flowINBP Free cash flowINBP Capital expendituresINBP Return on equityINBP Stock buybacksINBP Dividends paidINBP Total assetsINBP Total liabilitiesINBP Shareholders’ equityINBP overview →